Telomere length modulation in human astroglial brain tumors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Telomere length alterations are hallmarks of carcinogenesis and tumor progression across various cancer types.
• Telomere stability is maintained by telomerase (h-TERT) and protective proteins like Telomere Repeat-binding Factor (TRF) 1 and 2, and the tankyrase-PARP complex.

Purpose of the Study:

• To investigate telomere dysfunction in astroglial brain tumors.
• To analyze telomere length, telomerase activity, and gene expression of key telomere-regulating proteins in tumors of varying malignancy grades.

Main Methods:

• Analysis of Low Grade Astrocytomas (LGA), Anaplastic Astrocytomas (AA), and Glioblastoma Multiforme (GBM) tissue samples.
• Assessment of telomere length via Southern Blotting, telomerase activity using TRAP assay.
• Quantification of TRF1, TRF2, h-TERT, and TANKs-PARP complex expression through Immunoblotting and RT-PCR.

Main Results:

• Low Grade Astrocytomas exhibited upregulated TRF1 and TRF2 with shorter telomeres.
• Anaplastic Astrocytomas and Glioblastoma Multiforme showed downregulated TRF1 and TRF2, alongside upregulated telomerase and TANKs-PARP complex.

Conclusions:

• Upregulation of TRF1 and TRF2 in early astroglial tumors contributes to telomere shortening and genomic instability.
• Later stages are characterized by PARP-TANKs upregulation and telomerase activation, potentially leading to telomere elongation and malignant progression.